Spots Global Cancer Trial Database for Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Official Title: A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.
Study ID: NCT01254136
Conditions
Study Description
Brief Summary: This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Fayetteville, Arkansas, United States
, Duarte, California, United States
, Denver, Colorado, United States
, Davie, Florida, United States
, Jacksonville, Florida, United States
, Detroit, Michigan, United States
, St. Louis, Missouri, United States
, Hackensack, New Jersey, United States
, Lake Success, New York, United States
, Huntersville, North Carolina, United States
, Cincinnati, Ohio, United States
, Philadelphia, Pennsylvania, United States
, Nashville, Tennessee, United States
, Salt Lake, Utah, United States
Contact Details
Name: Denise A. Yardley, MD
Affiliation: Sara Cannon Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
